SOCIETY FOR BRAIN MAPPING AND THERAPEUTICS

SOCIETY FOR BRAIN MAPPING AND THERAPEUTICS

BREAKING BOUNDARIES OF SCIENCE, TECHNOLOGY, MEDICINE, ART & HEALTHCARE POLICY

Scientific Committee

Over 20 Subcommittees powering the therapeutics and tech innovation research and initiatives.

Scientific Committee

The Alzheimer’s Disease and Dementia SBMT Subcommittee, focuses on research on novel early diagnostics, therapeutics and management of Alzheimer’s disease and neurodegenerative diseases and dementia.

The Autism and Pediatric Neuroscience SBMT Subcommittee focuses on research on autism spectrum disorder and pediatrics neurological diseases, their implications diagnostics and therapeutics.

The Cerebrovascular and Skull base Surgery SBMT Subcommittee encompasses the divisions of neurosurgery, interventional neuroradiology, and AI endovascular surgery, all of which focus on a multidisciplinary approach to the treatment and care of various neurovascular diseases.

The Epilepsy, EEG, MEG, and NeuroRadiology SBMT Subcommittee, focuses on the functional aspects of neuro-imaging and associated research. MRI, MEG, PET, nuclear medicine, MRSI, MR-PET, DTI, CT-PET, focused ultrasound, MSI/MEG, ultra-high and low field MRI and interventional radiology, neurooncology, SRS, Gamma-Knife, Cyberknife, ZAP.

The Military Medicine and Veterans Health focuses on research regarding health for wounded soldiers and improvement of quality of life. PTSD, Traumatic Brain Injury, Mental Health, Neurotechnology, prosthetics, and Neurotrauma.

The NanoneuroSurgery and NeuroPhotonics SBMT Subcommittee focuses on research on the newest advances on nanotechnology for the purpose of neurosurgery and neurology. This subcommittee also explores the novel phtotonic applications in neurology and neurosciences in general.

The Neurooncology and Stem Cell SBMT Subcommittee, focuses on research on Brain cancer such as Glioblastoma, Astrocytoma and Meningiomas, their early molecular diagnosis, different therapeutic modalities (chemotherapy, radiation oncology, biologics, immunotherapy)

The Neuropsychiatric and Innovation SBMT Subcommittee, focuses on research on addiction, anxiety disorder, autism, sleep, medical imaging for psychiatric conditions, schizophrenia, depression, PTSD.

The Neuroscience20 SBMT Initiative subcommittee focuses on the global economical burden of neurological diseases and formulates resolutions given to the G20 leaders. It also leads an annual summit that is a think tank that serves this purpose, engaging in business plan workshops, health care policy issues that affect treatment delivery, usage of certain devices/drugs/imaging technologies, FDA regulations and reimbursements, federal and regional regulation impacting health care delivery and research funding, initiative and congressional legislation.

The Neurotechnology, Brain Computer Interface and Neuroengineering SBMT Subcommittee is for those who want to see the future, today. It dwells on the latests technological advances applied to neurosciences in general. AI Machine Learning.

The Psychedelics SBMT Subcommittee, focuses on research on the use of psychedelics for diverse neuropsychiatric illnesses.

The Spine Surgery SBMT subcommittee focuses on State-of-the-art diagnostic, surgical tools, and therapeutics. Some topics that we research are:
• Degenerative spine disease
• Spinal deformity (kyphosis/scoliosis)
• Spinal tumors (primary and metastatic bone tumors as well as intradural tumors)
• Spinal trauma
• Osteoporotic and geriatric spinal pathology
• Revision spinal surgery to treat failed fusions or adjacent level pathology
• Intraoperative CT scan and navigation systems
• State-of-the-art neuromonitoring
• CyberKnife radiosurgery
We specialize in traditional open and newer minimally invasive spinal techniques to treat the above pathologies.

The Visual Processing and Retinal Neuromodulation SBMT Subcommittee focuses on research on retinal processing and its impact on modulation
of autonomic, endocrine and limbic functions, visual influence on movement and behavior (including mental health diagnoses), effect of delayed visual development in autism and other developmental disabilities, visual circuitry disruptions from autonomic dysregulation, concussions and other brain injuries, advancements in optical assessments, sensory integration, virtual augmented/mixed reality.

Azra Raza, MD

Azra Raza, MD | KEYNOTE Annual World Congress SBMT 2024
Dr. Raza is a Professor of Medicine and Director of the MDS Center at Columbia University in New York, NY. She started her research in Myelodysplastic Syndromes (MDS) in 1982 and moved to Rush University, Chicago, Illinois in 1992, where she was the Charles Arthur Weaver Professor in Oncology and Director, Division of Myeloid Diseases. The MDS Program, along with a Tissue Repository containing more than 50,000 samples from MDS and acute leukemia patients was successfully relocated to the University of Massachusetts in 2004 and to Columbia University in 2010. Before moving to New York, Dr. Raza was the Chief of Hematology Oncology and the Gladys Smith Martin Professor of Oncology at the University of Massachusetts in Worcester. She has published the results of her laboratory research and clinical trials in prestigious, peer-reviewed journals such as The New England Journal of Medicine, Nature, Blood, Cancer, Cancer Research, the British Journal of Hematology, Leukemia, and Leukemia Research. Dr. Raza serves on numerous national and international panels as a reviewer, consultant, and advisor and is the recipient of a number of awards.

Thomas G. Schulze

Thomas G. Schulze, MD | KEYNOTE Annual World Congress SBMT 2024
Dr. Schulze’s research focuses on genotype-phenotype relationships in psychiatric disorders. He coordinates a German-wide center grant on longitudinal psychosis research and spearheads an international study on the genetic basis of response to lithium treatment in bipolar disorder, comprising several research groups from Europe, the Americas, Africa, Asia, and Australia. In addition, he and his team have embarked on population-based genetic studies in Ethiopia, focusing on the interplay of khat abuse (a plant that is used as a drug), trauma, and psychosis. Within the framework of a German government-funded, multi-site network, he is entrusted with the job of setting up a national federated biobanking and phenotyping platform.

Conor H Murray

Psychedelics Subcommittee | Neuropsychiatric Subcommittee
Conor H. Murray, PhD is a neuroscientist who has recently completed a postdoctoral fellowship (NIDA T32) at the University of Chicago. Trained on the neurobiology of substance use disorders, his prior work has spanned both preclinical and translational studies, from projects investigating the breakdown of endocannabinoid signaling during cocaine withdrawal to the acute cognitive effects of THC in adolescent men and women, and potential roles for LSD and MDMA in the treatment of anxiety, depression, and autism spectrum disorders

Jasmine Ramezanzadeh

2024 Program Coordinator | Intern 2023

Mojtaba Barzegar

PhD | CEO, Director SBMT Iran | Research Fellow (2021-2023)
Medical Physicist/ Researcher

Sara Lhassani

MD | Research Fellow (2023-2024)
Second-year resident in neurology in Morocco

Talha Nazir

MD | Research Fellow (2023-2024)

Mariia Bilorosiuk

MD | Research Scientist (2024), Lead Research Fellow (2023)

Unaiza Memon

MD | Research Fellow (2023)

Taha Kamal Tsouli

Intern (2023-2024)